RxDoctor Payments DataLook up a doctor →

Jorge Diez, MD

Endocrinology, Diabetes & Metabolism · East Hartford, CTNPI 1316940463

Payments from drug & device makers

$27,533in general payments, 2019–2025

Across 1,318 payments — averaging $20.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$3K
  • Medtronic$3K
  • Abbott$2K
  • Amgen$2K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • plus $14K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC144$2,637
Medtronic9$2,553
Abbott119$2,351
Amgen(2 entities)107$2,311
AstraZeneca(2 entities)97$1,656
Novo Nordisk119$1,606
Boehringer Ingelheim80$1,548
GSK62$1,276
Sanofi-aventis U.S. LLC51$934
Corcept Therapeutics36$881
Dexcom, Inc.36$866
AbbVie44$842
Mallinckrodt Hospital Products Inc.27$586
Pfizer27$472
Lifescan, Inc.29$439
Astellas Pharma US Inc16$367
Johnson & Johnson20$328
Exact Sciences12$325
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$318
Xeris Pharmaceuticals, Inc.18$316
Insulet Corporation11$306
Radius Health, Inc.13$274
Endo Pharmaceuticals Inc.15$259
Novartis11$236
Merck17$222
Neurocrine Biosciences, Inc.7$185
Bayer8$179
IBSA Pharma Inc.9$172
Amryt Pharma Holdings Ltd7$144
Antares Pharma, Inc.6$136
Takeda Pharmaceuticals U.S.A., Inc.6$136
Mannkind Corporation4$129
Ipsen Biopharmaceuticals, Inc7$114
Zealand Pharma US, Inc.4$108
Amarin Pharma, Inc.5$100
Ultragenyx Pharmaceutical Inc.5$89
Tandem Diabetes Care, Inc.3$88
Kyowa Kirin, Inc.5$87
Amneal Pharmaceuticals LLC5$82
Recordati_rare_diseases_inc.3$81
Shire North American Group Inc5$79
Harmony Biosciences LLC4$73
Lexicon Pharmaceuticals, Inc.4$72
Soleno Therapeutics, Inc.2$72
Halozyme Inc3$66
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$64
Ascendis Pharma Endocrinology Inc3$63
BD4$61
Chiesi USA, Inc.3$59
Acerus Pharmaceuticals Corporation4$58
Ascensia Diabetes Care US Inc.4$56
Teleflex LLC1$55
Otsuka America Pharmaceutical, Inc.3$55
Cequr Corporation2$52
Almatica Pharma LLC3$50
Biogen2$46
Amphastar Pharmaceuticals, Inc.2$46
Daiichi Sankyo Inc.2$45
Aytu Biopharma, Inc.3$43
Seqirus USA Inc2$36

How this compares

$27,533 in reported general payments places this provider in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.

See all endocrinology, diabetes & metabolism providers in Connecticut →

Medicare billing

Part B allowed, 2024
$89,775
Medicare patients
403
Services billed
1,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in East Hartford

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →